CTIS2022-501894-37-00招募中1 期
APalutamide and stEReotactic body radiation therapy for low burden metastatic hormone senSItive prostate cancer, a rANdomized trial -PERSIAN. - PERSIA
Fondazione Radioterapia Oncologica Onlus0 个研究点目标入组 180 人开始时间: 2022年11月4日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
- 入组人数
- 180
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 18 至 65+（—）
- 性别
- Male
入选标准
- •Patients who have signed written informed consent, Adult patients = 18 years, Oligometastatic hormone sensitive prostate cancer defined as presence of <= 5 non-visceral metastatic lesions, All lesions must be amenable to SBRT in judgment of treating radiation oncologist, Patients with metastatic recurrence after previous radical prostatectomy or definitive radiotherapy will be included in the trial, provided that radical approach on prostate is administered, Androgen deprivation therapy (ADT) started <= 6 months before enrollment, Patients should be eligible to Apalutamide treatment
排除标准
- •Presence of visceral disease, De novo metastatic disease, Any contraindication to the use of Apalutamide, Any condition for which, in the opinion of the treating physician, SBRT should not be proposed or could be contraindicated
研究者
相似试验
已完成
2 期
Apalutamide With or Without Stereotactic Body Radiation in Treating Castration-Resistant Prostate CancerCastration Levels of TestosteroneCastration-Resistant Prostate CarcinomaPSA ProgressionStage IV Prostate Adenocarcinoma AJCC v7NCT03503344University of California, San Francisco26
尚未招募
不适用
Stereotactic body radiation therapy after chemotherapy for unresectable perihilar cholangiocarcinoma: a multicenter phase II trial (The STRONG 2 trial)CholangiocarcinomaNL-OMON56809Erasmus MC, Universitair Medisch Centrum Rotterdam23
尚未招募
2 期
APalutamiAPalutamide and stEReotactic Body Radiation Therapy for Metastatic Prostate CancerOligometastatic Hormone Sensitive Prostate CancerNCT05717660Azienda Ospedaliero-Universitaria Careggi180
进行中（未招募）
1 期
Enzalutamide and hypofractionated radiation therapy in intermediate-risk localized prostate cancerMedDRA version: 19.1Level: PTClassification code 10060862Term: Prostate cancerSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2015-004617-25-ESFundación Canaria de Investigación Sanitarias
已完成
2 期
Stereotactic body radiotherapy followed by surgical stabilization for patients with painful unstable spinal metastases: First-in-man study according to the IDEAL recommendationsmetastatic spine tumorspinal metastases100059591002747610005944NL-OMON42087niversitair Medisch Centrum Utrecht13